Valuation: Cytosorbents Corporation

Market Cap 13.8M 12.14M 11.47M 10.41M 19.56M 1.32B 19.67M 137M 53.06M 676M 51.81M 50.69M 2.17B P/E 2026 *
-0.91x
P/E 2027 * -4.47x
Enterprise Value 13.8M 12.14M 11.47M 10.41M 19.56M 1.32B 19.67M 137M 53.06M 676M 51.81M 50.69M 2.17B EV / Sales 2026 *
0.35x
EV / Sales 2027 * 0.31x
Free-Float
84.01%
Yield 2026 *
-
Yield 2027 * -
1 day-8.22%
1 week-30.09%
Current month-41.06%
1 month-40.95%
3 months-44.48%
6 months-66.10%
Current year-68.55%
1 week 3.94
Extreme 3.94
5.59
1 month 3.94
Extreme 3.94
9.43
Current year 3.94
Extreme 3.94
16.89
1 year 3.94
Extreme 3.94
20.4
3 years 3.94
Extreme 3.94
43
5 years 3.94
Extreme 3.94
164.6
10 years 3.94
Extreme 3.94
299
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Buy

Chief Executive Officer

3,774 0.0060%
9/15/26 Buy

Director

2,500 0.0040%
9/14/26 Buy

Chairperson

2,073 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-8.22%-30.09%-78.47%-89.53% 13.8M
+0.53%+4.17%+46.17%+36.19% 250B
+1.27%+7.33%+22.99%-8.13% 158B
+2.37%+5.46%-5.97%+42.33% 143B
+0.43%+1.78%-55.07%-15.34% 63.65B
+0.63%-1.62%+13.88%+23.85% 49.74B
+1.40%+11.98%+42.00%+58.56% 48.71B
+2.33%+2.38%-14.54%-18.18% 47.94B
+2.17%+5.05%+51.84%+62.64% 42.59B
+0.70%+13.47%+196.54%+103.98% 40.77B
Average +0.04%+1.39%+21.94%+19.64% 84.4B
Weighted average by Cap. +0.75%+4.03%+27.31%+27.14%

Financials

2026 *2027 *
Net sales 38.88M 34.2M 32.32M 29.34M 55.1M 3.73B 55.42M 387M 149M 1.9B 146M 143M 6.12B 44.16M 38.84M 36.7M 33.32M 62.58M 4.24B 62.95M 439M 170M 2.16B 166M 162M 6.95B
Net income -13.91M -12.23M -11.56M -10.5M -19.71M -1.34B -19.83M -138M -53.48M -681M -52.22M -51.09M -2.19B -2.77M -2.44M -2.3M -2.09M -3.93M -266M -3.95M -27.57M -10.66M -136M -10.41M -10.18M -436M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-09-28 $4.020 -8.22% 14,254
26-09-25 $4.380 +1.86% 6,532
26-09-24 $4.300 -12.42% 24,869
26-09-23 $4.910 -7.71% 6,107
26-09-22 $5.320 -3.45% 6,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.380USD
Average target price
47.50USD
Spread / Average Target
+984.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock